News

MBC Alliance Welcomes More New Members


Metastatic Breast Cancer Alliance Welcomes More New Members in 2016

Nearly 50 leading public and private partners are working together to improve the lives of people living with metastatic breast cancer

December 8, 2016: The Metastatic Breast Cancer Alliance (“the Alliance”) welcomes the addition of 6 new organization members to its advocacy-led effort to accelerate research progress and increase awareness about the disease and patient care.

Cascadian Therapeutics joins other leading industry members all focused on innovative research projects and educational programs for people living with metastatic breast cancer. Cascadian Therapeutics is dedicated to the development of innovative therapies improving the lives and outcomes of metastatic HER2-positive breast cancer patients.

The Alliance is also thrilled to welcome five new nonprofit advocate organizations – ABCD: After Breast Cancer Diagnosis, the Cancer Couch Foundation, Hope Scarves, Male Breast Cancer Coalition and the Tigerlily Foundation.

“The Alliance has completed its third year with a very high level of productivity,” stated Dr. Marc Hurlbert, Chair of the Alliance and Chief Mission Officer of the Breast Cancer Research Foundation. “We have delivered over 15 initiatives in two years all designed to benefit metastatic breast cancer patients. With just one staff member this is a testament to the volunteer work of our members and their commitment to working together. We welcome our newest members who will join our longstanding partners in bringing their expertise to the table and actively working together to accomplish our vision.”

Metastatic patients have a median survival time of just three years—a statistic that, although improving, hasn’t changed dramatically in two decades. More than 40,000 Americans are projected to die of metastatic breast cancer in 2016.

The Alliance, comprised of nearly 50 members, is the only breast cancer coalition of nonprofit groups, survivors, individuals living with metastatic breast cancer, and industry partners in the U.S. focused 100 per cent on metastatic breast cancer. Members work together to speed up the progress of scientific research, increase patient support and improve public education about metastatic breast cancer.

Since its 2014 landmark report, Changing the Landscape for People Living with Metastatic Breast Cancer, the Alliance has been actively working to close gaps for people living with metastatic breast cancer in research, clinical trials, quality of life, patient education and support services, and epidemiology. Its initiatives have included gathering more than 55 key opinion leader insights from research centers, pharmaceutical companies, the FDA and NCI on how to remove barriers to progress in research, creating a data visualization tool for clinical trials, piloting a prototype of a communication toolkit to improve conversations between health care professionals and patients, and developing public awareness campaigns.

For more information, visit mbcalliance.org and follow MBCA on Facebook (/mbcalliance), Twitter (@mbcalliance), and YouTube (MBCAllianceVideos).

Contact: Katherine Crawford-Gray, Director, MBC Alliance, Mobile: 646-379-1855